At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 60 enrolled
Drug / intervention
Mexidoldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective Randomized Study of the Modulating Effect of MEXIDOL® as an Adjuvant Stimulant of the Cognitive-emotional Component of the Rehabilitation Treatment in Patients With Acute Cerebral Failure
In Brief
A Phase 4 clinical trial evaluating Mexidol for Ischemic Stroke, Acute. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The use of metabolic modulators creates prospects for increasing the efficiency of the rehabilitation treatment of patients with acute cerebral failure
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIschemic Stroke, Acute
CountriesRussia
Collaborators--
Timeline
Phase 4CompletedFinished
202420252026
Enrollment StartApr 2023
Primary CompletionSep 2023
First PostedJan 2024
TodayJul 2026
First PostedJan 24, 2024
Enrollment StartApr 17, 2023
Primary CompletionSep 12, 2023
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 2.4 years ago
Interventions
Mexidoldrug
Neurocytoprotector